A Phase 2 Trial for Patients With Metastatic Solid Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 19, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Metastatic Cancer
Interventions
DRUG

Keytruda Injectable Product

"Keytruda (pembrolizumab): PD-1 inhibitor antibody~Injectable 50mg/mL, only 2 mL injected."

DRUG

Yervoy Injectable Product

"Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 2 mL injected."

DRUG

Cytoxan

Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: 50mg once daily pill for 5 days prior to first treatment, 3 days prior to 2nd and 3rd treatment.

PROCEDURE

Cryosurgical freezing (cryosurgery)

Cryosurgery, also known as cryoablation, for metastatic cancer works by freezing the cancer cells inside the tumor. Cryoablation will release intact antigens to prime the immune system.

DRUG

GM-CSF Injectable

Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days post after each treatment.

Trial Locations (1)

48307

Ascension Providence Rochester Hospital, Rochester

All Listed Sponsors
lead

Rampart Health, L.L.C.

INDUSTRY

NCT04713371 - A Phase 2 Trial for Patients With Metastatic Solid Cancer | Biotech Hunter | Biotech Hunter